- Home
- KINS vs CADL Comparison
KINS vs CADL Comparison
Compare KINS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- CADL
- Stock Information
- Founded
- KINS 1886
- CADL 1999
- Country
- KINS United States
- CADL United States
- Employees
- KINS N/A
- CADL N/A
- Industry
- KINS Property-Casualty Insurers
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KINS Finance
- CADL Health Care
- Exchange
- KINS Nasdaq
- CADL Nasdaq
- Market Cap
- KINS 197.1M
- CADL 234.8M
- IPO Year
- KINS N/A
- CADL 2021
- Fundamental
- Price
- KINS $21.67
- CADL $4.81
- Analyst Decision
- KINS Strong Buy
- CADL Strong Buy
- Analyst Count
- KINS 1
- CADL 4
- Target Price
- KINS $6.50
- CADL $21.00
- AVG Volume (30 Days)
- KINS 381.5K
- CADL 843.6K
- Earning Date
- KINS 05-08-2025
- CADL 05-20-2025
- Dividend Yield
- KINS N/A
- CADL N/A
- EPS Growth
- KINS 5417.04
- CADL N/A
- EPS
- KINS 1.60
- CADL N/A
- Revenue
- KINS $169,875,701.00
- CADL N/A
- Revenue This Year
- KINS $40.63
- CADL N/A
- Revenue Next Year
- KINS $6.92
- CADL N/A
- P/E Ratio
- KINS $13.35
- CADL N/A
- Revenue Growth
- KINS 18.52
- CADL N/A
- 52 Week Low
- KINS $4.01
- CADL $3.79
- 52 Week High
- KINS $20.16
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KINS 67.78
- CADL 42.39
- Support Level
- KINS $16.60
- CADL $4.34
- Resistance Level
- KINS $18.88
- CADL $5.34
- Average True Range (ATR)
- KINS 1.38
- CADL 0.33
- MACD
- KINS 0.20
- CADL 0.10
- Stochastic Oscillator
- KINS 91.06
- CADL 47.11
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.